A new medical therapy for anemia in thalassemia
- PMID: 30898772
- DOI: 10.1182/blood-2019-01-897587
A new medical therapy for anemia in thalassemia
Conflict of interest statement
Conflict-of-interest disclosure: E.A. received honoraria from Novartis and Celgene, participated in local advisory boards for Jazz Pharmaceuticals, bluebird bio, and Roche, and participated in data monitoring committee for Celgene, Vertex Pharmaceuticals, and CRISPR Therapeutics.
Comment on
-
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7. Blood. 2019. PMID: 30617198 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

